Clinical Trial: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)

Study Status: No longer available
Recruit Status: No longer available
Study Type: Expanded Access

Official Title: Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma

Brief Summary:

In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR (e.g. Named Patient Program (NPP)). For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and

continue to meet eligibility will transition to an extension phase of the study and the base study will be closed.

The extension phase will begin as soon as the protocol amendment is implemented.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome:

Original Primary Outcome: To provide drug on a compassionate use basis for the treatment of skin lesions in patients with CTCL who have been previously treated with at least two systemic medications.

Current Secondary Outcome:

Original Secondary Outcome: To assess the safety and efficacy of vorinostat in patients with CTCL.

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: January 5, 2007
Date Started:
Date Completion:
Last Updated: May 9, 2017
Last Verified: May 2017